Skip over navigation
Banner
Directory
Directory Search
Jobs
Job Search Post a Job
Patient
Patient Resources Drug Development
History
Genealogy
Toons & Teasers
Industry
 Directory
 Toons & Teasers
Quick Links
 Directory
 Job Search
 Toons & Teasers
 Advertising
 
Jobs
 

EquipNet Auction: Sell Your Surplus Equipment on Our Global Marketplace Now!

Our Newest Cartoon Illustrates: "The Biology of Valentines"


Washington Life Science Industry Directory

https://www.cdc.gov/flu/prevent/index.html

Banner Advertising

Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved directory upon the launch of the new site. We apologize for the inconvenience.

Emergent BioSolutions Inc.


Emergent BioSolutions Inc.
2401 4th Ave., Suite 1050
Seattle, WA 98121
Emergent BioSolutions Inc.
 
Phone: (206) 838-0500
Fax: (206) 838-0503
Year Established:  2002
Employees: 73
Ticker: EBS
Exchange: NYSE
 
Other Contacts:  Shauna M. Tholen, Senior VP & CIO
Allen Shofe, Executive VP, Corporate Affairs Division
Katy Strei, Senior VP, Chief Human Resources Officer
Robert G. Kramer, Executive VP & CFO
W. James Jackson, Ph.D., Senior VP & CSO
Adam R. Havey, Executive VP & President, BioDefense Division
Daniel J. Abdun-Nabi, President & CEO
 
Company Description

Emergent BioSolutions Seattle (formerly Trubion Pharmaceuticals) is a global biopharmaceutical company focused on the manufacture, development and commercialization of vaccines and antibody therapeutics. Trubion’s clinical and preclinical stage programs, as well as its novel technology platforms, will expand Emergent’s product development pipeline into the key disease indications of oncology and autoimmunity, and significantly broaden its antibody-based capabilities. The Seattle, Washington facility is now known as Emergent Product Development Seattle and will continue to focus on developing unique therapeutic products.

On August 12, 2010, Emergent BioSolutions announced an agreement to acquire Trubion Pharmaceuticals for upfront consideration of $96.8 million of value and up to $38.7 million of success-based milestones, resulting in a total consideration of up to $135.5 million.



Main Industry Directory

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page
© 1997 - 2023 Info.Resource, Inc. All rights reserved.
Privacy Policy . Cookie Policy . Terms of Use . About . Advertising

WashingtonLifeScience.com is owned and published by Info.Resource, Inc.